Influenza A (H5N1): Will it be the next pandemic influenza? Are we ready?

Annals of Internal Medicine

Volumn 143, Issue 6, 2005, Pages 460-462

  Bartlett, John G ^a,c   Hayden, Frederick G ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AVIAN INFLUENZA; CHILD; CLINICAL FEATURE; EPIDEMIC; FATALITY; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION; EDITORIAL; INFLUENZA VIRUS A H5N1; UNITED STATES; VIROLOGY;

DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; UNITED STATES;

EID: 24944535757     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-143-6-200509200-00011     Document Type: Review

References (23)

1. Abbott A, Cyranoski D. Bird flu sparks worldwide bid to prevent human pandemic. Nature. 2004;427:274. [PMID: 14737129]
2. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature. 2004;432:904-6. [PMID: 15602562]
3. Palese P. Influenza: old and new threats. Nat Med. 2004;10:582-7. [PMID: 15577936]
4. Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature. 2004:431:703-7. [PMID: 15470432]
5. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 1998;351:472-7. [PMID: 9482438]
6. Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev. 2001;14:129-49. [PMID: 11148006]
7. Katz JM, Lim W, Bridges CB, Rowe T, Hu-Primmer J, Lu X, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis. 1999;180:1763-70. [PMID: 10558929]
8. Stöhr K. Avian influenza and pandemics-research needs and opportunities [Editorial]. N Engl J Med. 2005;352:405-7. [PMID: 15668221]
9. Hatta NM, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 2001;293:1840-2. [PMID: 11546875]
10. Harvey R, Martin AC, Zambon M, Barclay WS. Restrictions to the adaptation of influenza a virus h5 hemagglutinin to the human host. J Virol. 2004;78:502-7. [PMID: 14671130]
11. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet. 2004;363:1099-103. [PMID: 15064027]
12. Treanor JJ, Kotloff K, Belts RF, Belshe R, Newman F, Iacuzio D, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999;18:899-906. [PMID: 10580204].
13. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 2001;357:1937-43. [PMID: 11425416]
14. Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis. 2005;191:1210-5. [PMID: 15776364]
15. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother. 2001;45:1216-24. [PMID: 11257037]
16. Gubareva LV, McCullers JA, Bethell RC, Webster RG. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis. 1998;178:1592-6. [PMID: 9815209]
17. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000;48:101-15. [PMID: 11114412]
18. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005;55 Suppl 1:i5-i21. [PMID: 15709056]
19. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352:333-40. [PMID: 15668219]
20. Shortridge KF. Pandemic influenza: a zoonosis? Semin Respir Infect. 1992;7:11-25. [PMID: 1609163]
21. Profeta ML, Palladino G. Serological evidence of human infections with avian influenza viruses. Brief report. Arch Virol. 1986;90:355-60. [PMID: 3729733]
22. Pavia A. Pantemic influenza. Statement of the Infectious Diseases Society of America before the House Committee on Energy and Commerce Subcommittee on Health. Accessed at www.idsociety.org on 26 May 2005.
23. Osterholm MT. Preparing for the next pandemic. N Engl J Med. 2005;352: 1839-42. [PMID: 15872196]